Enalaprilat: uses, dosing, side effects & brands
Enalaprilat is an angiotensin converting enzyme inhibitor sold in the U.S. under one brand, for rheumatoid arthritis, bartter syndrome and diabetic nephropathies. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Drug class
- Angiotensin Converting Enzyme Inhibitor
- Treats
- Rheumatoid Arthritis, Bartter Syndrome and Diabetic Nephropathies
- Available as
- Injectable
- Sold as
- Enalaprilat
- Prescription?
- Prescription only
- Generic available?
- Yes
- Boxed warning
- Boxed warning
How enalaprilat is dosed
From the FDA label for Enalaprilat (application ANDA075458). Other enalaprilat products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
The dose in hypertension is 1.25 mg every six hours administered intravenously over a five minute period. A clinical response is usually seen within 15 minutes. Peak effects after the first dose may not occur for up to four hours after dosing. The peak effects of the second and subsequent doses may exceed those of the first. No dosage regimen for enalaprilat injection, USP has been clearly demonstrated to be more effective in treating hypertension than 1.25 mg every six hours. However, in controlled clinical studies in hypertension, doses as high as 5 mg every six hours were well tolerated for up to 36 hours. There has been inadequate experience with doses greater than 20 mg per day. In studies of patients with hypertension, enalaprilat injection, USP has not been administered for periods longer than 48 hours. In other studies, patients have received enalaprilat injection, USP for as long as seven days. The dose for patients being converted to enalaprilat injection, USP from oral therapy for hypertension with enalapril maleate is 1.25 mg every six hours. For conversion from intravenous to oral therapy, the recommended initial dose of Tablets VASOTEC (Enalapril Maleate) is 5 mg once a day with subsequent dosage adjustments as necessary. Patients On Diuretic Therapy For patients on diuretic therapy the recommended starting dose for hypertension is 0.625 mg administered…
Enalaprilat side effects
Enalaprila injection, USP has been found to be generally well tolerated in controlled clinical trials involving 349 patients (168 with hypertension, 153 with congestive heart failure and 28 with coronary artery disease). The most frequent clinically significant adverse experience was hypotension (3.4 percent), occurring in eight patients (5.2 percent) with congestive heart failure, three (1.8 percent) with hypertension and one with coronary artery disease. Other adverse experiences occurring in greater than one percent of patients were: headache (2.9 percent) and nausea (1.1 percent). Adverse experiences occurring in 0.5 to 1.0 percent of patients in controlled clinical trials included: myocardial infarction, fatigue, dizziness, fever, rash and constipation. Angioedema: Angioedema has been reported in patients receiving enalaprilat, with an incidence higher in black than in non-black patients. Angioedema associated with laryngeal edema may be fatal. If angioedema of the face, extremities, lips, tongue, glottis and/or larynx occurs, treatment with enalaprilat should be discontinued and appropriate therapy instituted immediately (see WARNINGS ). Cough: See PRECAUTIONS , Cough. Enalapril Maleate Since enalapril is converted to enalaprilat, those adverse experiences associated with enalapril might also be expected to occur with enalaprilat injection, USP. The following adverse…
Who shouldn’t take enalaprilat
Enalaprilat injection, USP is contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angioedema related to previous treatment with an angiotensin converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema.
Enalaprilat and food
Potassium-rich foods & salt substitutes
Don't use potassium-based salt substitutes unless your clinician approves, and ask before taking potassium supplements. Your clinician may check your potassium level with blood tests.
Lisinopril (an ACE inhibitor) — MedlinePlus (U.S. National Library of Medicine) ↗
Every enalaprilat product we track (1)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
Only one: Enalaprilat.
How long enalaprilat keeps
No enalaprilat label we read sets a separate limit for after opening, but they do specify how it must be stored — and the stability behind any date assumes those conditions.
Does enalaprilat expire? The in-use limits and storage rules from its labelsWhat people report to the FDA about enalaprilat
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 357 reports naming enalaprilat, and the FDA flagged 77% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- acute kidney injury19 reports
- heart rate decreased19 reports
- hypertension19 reports
- nausea19 reports
- angioedema18 reports
- blood pressure systolic abnormal18 reports
- blood pressure systolic increased18 reports
- drug hypersensitivity18 reports
Read these as a signal, not a rate. A report does not mean enalaprilat caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.
Source: openFDA drug/event (FAERS), retrieved July 25, 2026.
Related guides
Related calculators
Frequently asked questions
What is enalaprilat?
Enalaprilat is an angiotensin converting enzyme inhibitor used to treat Rheumatoid Arthritis, Bartter Syndrome, Diabetic Nephropathies, Edema.
What kind of drug is enalaprilat?
The FDA classifies enalaprilat as an angiotensin converting enzyme inhibitor. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.
Can you take enalaprilat with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run enalaprilat against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What forms does enalaprilat come in?
Across the brands we track, enalaprilat is currently marketed as injectable, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic enalaprilat?
Yes. Our catalog lists 1 generic enalaprilat product alongside the brand versions. A generic has the same active ingredient and must meet the FDA's bioequivalence standard; it usually costs less. Ask your pharmacist which one your plan covers.
What should I avoid while taking enalaprilat?
Food: salt substitutes containing potassium, and large amounts of potassium-rich foods or supplements — see the food section above for what each one does and whether it means avoiding it or just being consistent. This is what the FDA label and our cited sources say — it is not a complete list. Your pharmacist can check your own combination.
Cite this page
- APA
- pharmaranks. (2026, July 24). Enalaprilat: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/enalaprilat
- MLA
- “Enalaprilat: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/enalaprilat.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for enalaprilat on DailyMed (NIH) ↗ — including its boxed warning in full.